Sarepta gains after Pfizer's late-stage setback for Duchenne therapy [Seeking Alpha]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Seeking Alpha
three consecutive sessions of losses after Pfizer ( NYSE: PFE ) said its candidate for the neuromuscular disorder failed in a Phase 3 trial. In a press release late Wednesday, New York-based Pfizer ( PFE ) said its gene therapy candidate, fordadistrogene movaparvovec, did not reach the primary endpoint in boys aged 4–7 years with DMD. Pfizer ( PFE ) shares moved marginally lower following the announcement, while Sarepta ( SRPT ) inched higher on low volumes. Elevidys, a gene therapy developed by Sarepta ( SRPT ) with Roche ( OTCQX:RHHBY OTCQX:RHHBF ), is currently under FDA priority review. In June 2023, the FDA granted accelerated approval for Elevidys with a narrower-than-expected label for children aged 4–5 with DMD. The FDA decision on whether to grant the one-time therapy full approval with a broader label is expected on or before June 21, 2024. Recommended For You Recommended For You More Trending News Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. [Yahoo! Finance]Yahoo! Finance
- Moderna says its RSV shot is 50% effective after 18 months [CNBC]CNBC
- Obesity Pipeline Research 2024: Insights About 80+ Companies and 100+ Pipeline Drugs - Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]Yahoo! Finance
- Capvaxive will enhance protection against pneumococcal disease in older adults [Yahoo! Finance]Yahoo! Finance
- Meet The University College London (UCL) School Of Management MBA Class Of 2025 [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- 6/11/24 - Form 11-K
- PFE's page on the SEC website